MLTX — MoonLake Immunotherapeutics
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1821586 ·
Last close
$10.58
Market Cap
$900.43M
52W High
$23.29
52W Low
$8.80
ADV30
1,746,633
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -61,660,000 | -61,805,000 | 573,947,000 | 477,905,000 | 145,752,000 |
| Mar 2026 | 0 | — | -70,024,000 | -69,707,000 | 400,374,000 | 298,490,000 | 146,350,000 |
| Dec 2025 | 0 | — | -65,218,000 | -62,427,000 | 424,433,000 | 334,517,000 | 119,952,000 |
| Sep 2025 | 0 | — | -71,434,000 | -69,729,000 | 414,335,000 | 350,736,000 | 123,144,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-224,153,000
Investing CF
$146,844,000
Financing CF
$103,519,000
CapEx
$-210,567
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.58
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-532,618,000
Inventory
—
Receivables
$5,763,000
ST Investments
$59,431,000
EBIT TTM
$-248,892,000
Pretax Income TTM
$-258,390,000
Interest Exp TTM
$9,498,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -244,834,000 | -227,318,000 | 424,433,000 | 119,952,000 | 304,481,000 | -196,007,000 |
| Dec 2024 | 0 | -143,091,000 | -118,936,000 | 477,933,000 | 24,542,000 | 446,825,000 | -116,587,000 |
| Dec 2023 | 0 | -54,123,000 | -36,007,000 | 526,540,115 | 13,049,096 | 495,675,683 | -42,778,000 |
| Dec 2022 | 0 | -65,061,417 | -49,973,249 | 76,843,301 | 8,076,603 | 48,898,296 | -55,893,900 |
TTM Snapshot
Revenues TTM
$-534,746,000
NetIncome TTM
$-257,081,000
OpCashFlow TTM
—
Assets (Latest)
$400,374,000
Forward EPS
$-3.33
Max Pain — expiry 2026-10-16
max pain strike: $12.00 · spot: $10.85 · call oi: 4,825 · put oi: 293
Expected Move to 2026-10-16:
±$1.02
(9.45%) —
implied range
$9.83 –
$11.88
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | $899.90M | $14.15 | — |
| ALMS | ALUMIS INC. | $902.16M | $6.97 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $910.08M | $48.72 | — |
| ANL | Adlai Nortye Group Ltd. | $910.97M | $15.51 | — |
| TBPH | Theravance Biopharma, Inc. | $884.18M | $17.03 | — |
News headlines (Yahoo Finance, 1h cache)
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
2026-10-05 15:26 · Yahoo
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
2026-09-11 17:48 · Yahoo
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
2026-08-10 13:24 · Yahoo
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
2026-08-03 17:30 · Yahoo
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
2026-07-31 13:55 · Yahoo
MoonLake Immunotherapeutics' CFO Sells 39K Shares
2026-07-03 14:34 · Yahoo
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
2026-06-30 13:22 · Yahoo
How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering
2026-06-25 12:07 · Yahoo
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
2026-06-25 00:09 · Yahoo
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
2026-06-24 11:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.